Efficacy of ledipasvir/sofosbuvir with or without ribavirin for 12 weeks in genotype 1b HCV patients previously treated with a nonstructural protein 5A inhibitor ‐containing regimen
ConclusionsThe addition of RBV to 12 weeks of LDV/SOF has little therapeutic benefit when retreating patients in whom a prior NS5A inhibitor‐containing regimen had failed. (Source: Hepatology Research)
Source: Hepatology Research - March 1, 2018 Category: Internal Medicine Authors: Hiroki Ikeda, Tsunamasa Watanabe, Hirohito Shimizu, Tetsuya Hiraishi, Rena Kaneko, Toshiyuki Baba, Hideaki Takahashi, Kotaro Matsunaga, Nobuyuki Matsumoto, Hiroshi Yasuda, Chiaki Okuse, Shogo Iwabuchi, Michihiro Suzuki, Fumio Itoh Tags: Original Article Source Type: research
The formation of p62 ‐positive inclusion body is associated with macrophage polarization in non‐alcoholic fatty liver disease
ConclusionsThese findings indicate that chronic inflammation by M1‐poralization of macrophages contributes to the disease progression from simple steatosis to NASH in concert with autophagic dysfunction. (Source: Hepatology Research)
Source: Hepatology Research - February 23, 2018 Category: Internal Medicine Authors: Hirofumi Fukushima, Shunhei Yamashina, Atsushi Arakawa, Gentaro Taniguchi, Tomonori Aoyama, Akira Uchiyama, Kazuyoshi Kon, Kenichi Ikejima, Sumio Watanabe Tags: Original Article Source Type: research
Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease
Hepatology Research, EarlyView. (Source: Hepatology Research)
Source: Hepatology Research - February 21, 2018 Category: Internal Medicine Source Type: research
Genetic variants in NTCP exon gene are associated with HBV infection status in a Chinese Han population
Hepatology Research, EarlyView. (Source: Hepatology Research)
Source: Hepatology Research - February 21, 2018 Category: Internal Medicine Source Type: research
---
Hepatology Research, Ahead of Print. (Source: Hepatology Research)
Source: Hepatology Research - February 21, 2018 Category: Internal Medicine Source Type: research
A promising medium ‐term follow‐up of pediatric sclerosing cholangitis: Mild phenotype or early diagnosis?
Hepatology Research, EarlyView. (Source: Hepatology Research)
Source: Hepatology Research - February 19, 2018 Category: Internal Medicine Source Type: research
Intrahepatic bile duct primary cilia in biliary atresia
Hepatology Research, EarlyView. (Source: Hepatology Research)
Source: Hepatology Research - February 19, 2018 Category: Internal Medicine Source Type: research
---
Hepatology Research, Ahead of Print. (Source: Hepatology Research)
Source: Hepatology Research - February 19, 2018 Category: Internal Medicine Source Type: research
A promising medium ‐term follow‐up of pediatric sclerosing cholangitis: Mild phenotype or early diagnosis?
ConclusionsIn our early diagnosed cohort, the 9‐year survival with native liver was better than that reported in other studies. Approximately 15% of patients developed liver‐related disease complications, less than previously reported. The long‐term course of SC was negatively influenced by the presence of autoimmune features, but not by concomitant IBD. (Source: Hepatology Research)
Source: Hepatology Research - February 19, 2018 Category: Internal Medicine Authors: Federica Ferrari, Giusy Ranucci, Marina Aloi, Luca Della Volpe, Franca Viola, Erasmo Miele, Salvatore Cucchiara, Raffaele Iorio Tags: Original Article Source Type: research
Intrahepatic bile duct primary cilia in biliary atresia
ConclusionsThe presence of IHBC in BA livers at the diagnosis was associated with resolution of cholestasis, although was not predictive of short‐term survival with native liver. Scanning electron microscopy represents a powerful new tool to study routine liver biopsies in biliary disorders. Cilia dysfunction in BA pathogenesis and/or disease progression warrants further investigation. (Source: Hepatology Research)
Source: Hepatology Research - February 19, 2018 Category: Internal Medicine Authors: Roberta Frassetto, Filippo Parolini, Salvatore Marceddu, Giulia Satta, Valeria Papacciuoli, Maria Antonia Pinna, Alessandra Mela, Giannina Secchi, Grazia Galleri, Roberto Manetti, Luisa Bercich, Vincenzo Villanacci, Antonio Dessanti, Roberto Antonucci, Fr Tags: Original Article Source Type: research
Cost ‐effectiveness analyses of anti‐hepatitis C virus treatments using quality of life scoring among patients with chronic liver disease in Hiroshima prefecture, Japan
Hepatology Research, EarlyView. (Source: Hepatology Research)
Source: Hepatology Research - February 17, 2018 Category: Internal Medicine Source Type: research
---
Hepatology Research, Ahead of Print. (Source: Hepatology Research)
Source: Hepatology Research - February 17, 2018 Category: Internal Medicine Source Type: research
Cost ‐effectiveness analyses of anti‐hepatitis C virus treatments using quality of life scoring among patients with chronic liver disease in Hiroshima prefecture, Japan
ConclusionsDirect‐acting antiviral treatment was estimated to be cost‐effective from 10 to 25 years after treatment, depending on the SVR rate of the drugs and the age of onset of treatment. In order to increase the cost‐effectiveness of DAA treatment, measures or effort to improve the QOL score of patients after SVR are necessary. (Source: Hepatology Research)
Source: Hepatology Research - February 17, 2018 Category: Internal Medicine Authors: Terumi Kaishima, Tomoyuki Akita, Masayuki Ohisa, Kazuaki Sakamune, Akemi Kurisu, Aya Sugiyama, Hiroshi Aikata, Kazuaki Chayama, Junko Tanaka Tags: Original Article Source Type: research
